Application and mechanism of Action of lisdexamfetamine (ldx) in The treatment of attention and compulsion disorders
DOI:
https://doi.org/10.56294/piii2024322Keywords:
Lisdexamfetamine and ADHD, lisdexamfetamine and binge eating disorder, lisdexamfetamine and methylphenidateAbstract
Background: Attention Deficit Hyperactivity Disorder (ADHD), widely known as attention deficit disorder, currently represents a critical issue in the fields of public health and mental health, affecting populations from childhood to adulthood. It is estimated that 3% of the adult population is affected by this disorder, and this has significant implications in the daily lives of affected individuals.
Patients experiencing ADHD often face notable difficulties in areas such as maintaining attention, impulse regulation, and behavioral control. Characteristic symptoms include inattention, hyperactivity, and impulsivity. ADHD is addressed therapeutically through a multidisciplinary approach that combines behavioral therapies and the use of medicinal agents, including both stimulant and non-stimulant drugs. These therapeutic resources help improve the ability to concentrate, impulse control, and, therefore, the quality of life of affected individuals. In recent years, Lisdexamfetamine has gained prominence as a first-line therapeutic alternative in the treatment of ADHD, standing out for its superior efficacy compared to predecessor agents such as methylphenidate (marketed under the name Ritalin), modafinil, guanfacine, and paroxetine. In addition to its application in the context of ADHD, lisdexamfetamine is being explored as an adjuvant intervention in the treatment of binge eating disorder. This disorder is characterized by recurrent episodes of excessive food intake in a short period, accompanied by a perception of a lack of control during such episodes. Binge eating can lead to physical and emotional distress and have a negative impact on the overall health and well-being of affected individuals. Lisdexamfetamine is proposed as a possible solution to alleviate the symptoms of binge eating disorder, with the potential to reduce the frequency of compulsive episodes and promote a greater perception of control over eating. Material and methods: A systematic review will be carried out that includes exploration in databases such as Pubmed and Google Scholar, using filters related to Attention Deficit Disorder, Binge Eating Disorder, and adverse effects. Results: 8 randomized trial articles were used, searched in the databases, and filtered based on the last two years, where the application and mechanism of LISDEXAMPHETAMINE (LDX) in the treatment of attention and compulsive eating disorders were evidenced. Conclusion: After the search carried out, it is understood that LISDEXAMPHETAMINE (LDX) in recent years has gained prominence as a first-line therapeutic alternative in the treatment of ADHD, standing out for its superior efficacy compared to predecessor agents. However, other specialized studies are also required to evaluate possible side effects, both therapeutic and adverse effects
References
Stuhec M, Lukić P, Locatelli I. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Ann Pharmacother. fevereiro de 2019;53(2):121–33.
Herrero MJP, Hierro RS. Seguimiento de los efectos de una intervención psicosocial sobre la adaptación académica, emocional y social de niños con TDAH.
Childress AC, Lloyd E, Jacobsen L, Gunawardhana L, Johnson SA, Findling RL. Efficacy and Safety of
Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. dezembro de 2022;61(12):1423–34.
Quintero J, Gutiérrez-Casares JR, Álamo C. Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review. Neurol Ther. dezembro de 2022;11(4):1489–517.
Torres-Acosta N, O’Keefe JH, O’Keefe CL, Lavie CJ. Cardiovascular Effects of ADHD Therapies. J Am Coll Cardiol. agosto de 2020;76(7):858–66.
Findling RL, Childress AC, Krishnan S, McGough JJ. Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. CNS Spectr. julho de 2008;13(7):614–20.
Padilha SCOS, Virtuoso S, Tonin FS, Borba HHL, Pontarolo R. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. Eur Child Adolesc Psychiatry. outubro de 2018;27(10):1335–45.
Griffiths KR, Aparício L, Braund TA, Yang J, Harvie G, Harris A, et al. Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder. Front Psychol. 31 de agosto de 2021;12:716010.
Schneider E, Higgs S, Dourish CT. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. Eur Neuropsychopharmacol. dezembro de – ;53:49 78.
Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, et al. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. Drug Alcohol Depend. dezembro de 2022;241:109692.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Camila Andrada Santos, Marcelo Adrian Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
